A Phase 2a Study Evaluating the Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis.

Trial Profile

A Phase 2a Study Evaluating the Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Oxybutynin/pilocarpine (Primary) ; Oxybutynin
  • Indications Hyperhidrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TheraVida
  • Most Recent Events

    • 27 Feb 2017 Results published in a TheraVida Media Release.
    • 27 Feb 2017 Results were published in the February 2017 issue of the Journal of Drugs in Dermatology, according to a TheraVida media release.
    • 03 Oct 2016 Primary endpoint (Changes from baseline to end of treatment in symptoms associated with PFH) has been met, according to a TheraVida media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top